Beta Bionics Statistics
Total Valuation
Beta Bionics has a market cap or net worth of $1.19 billion. The enterprise value is $991.44 million.
Important Dates
The last earnings date was Tuesday, October 28, 2025, after market close.
| Earnings Date | Oct 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Beta Bionics has 44.02 million shares outstanding. The number of shares has increased by 401.81% in one year.
| Current Share Class | 44.02M |
| Shares Outstanding | 44.02M |
| Shares Change (YoY) | +401.81% |
| Shares Change (QoQ) | +0.56% |
| Owned by Insiders (%) | 3.67% |
| Owned by Institutions (%) | 76.24% |
| Float | 24.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.55 |
| Forward PS | 9.98 |
| PB Ratio | 4.05 |
| P/TBV Ratio | 4.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.64, with a Debt / Equity ratio of 0.03.
| Current Ratio | 10.64 |
| Quick Ratio | 9.57 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -47.52% and return on invested capital (ROIC) is -25.03%.
| Return on Equity (ROE) | -47.52% |
| Return on Assets (ROA) | -20.08% |
| Return on Invested Capital (ROIC) | -25.03% |
| Return on Capital Employed (ROCE) | -22.52% |
| Revenue Per Employee | $301,259 |
| Profits Per Employee | -$264,769 |
| Employee Count | 294 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 2.54 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 23.60 |
| 200-Day Moving Average | 17.76 |
| Relative Strength Index (RSI) | 58.42 |
| Average Volume (20 Days) | 760,979 |
Short Selling Information
The latest short interest is 3.60 million, so 8.19% of the outstanding shares have been sold short.
| Short Interest | 3.60M |
| Short Previous Month | 4.17M |
| Short % of Shares Out | 8.19% |
| Short % of Float | 14.97% |
| Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, Beta Bionics had revenue of $88.57 million and -$77.84 million in losses. Loss per share was -$2.50.
| Revenue | 88.57M |
| Gross Profit | 48.28M |
| Operating Income | -68.59M |
| Pretax Income | -77.84M |
| Net Income | -77.84M |
| EBITDA | -67.33M |
| EBIT | -68.59M |
| Loss Per Share | -$2.50 |
Full Income StatementBalance Sheet
The company has $228.69 million in cash and $7.69 million in debt, giving a net cash position of $221.00 million or $5.02 per share.
| Cash & Cash Equivalents | 228.69M |
| Total Debt | 7.69M |
| Net Cash | 221.00M |
| Net Cash Per Share | $5.02 |
| Equity (Book Value) | 294.76M |
| Book Value Per Share | 6.70 |
| Working Capital | 244.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$56.58 million and capital expenditures -$3.96 million, giving a free cash flow of -$60.53 million.
| Operating Cash Flow | -56.58M |
| Capital Expenditures | -3.96M |
| Free Cash Flow | -60.53M |
| FCF Per Share | -$1.37 |
Full Cash Flow StatementMargins
Gross margin is 54.51%, with operating and profit margins of -77.45% and -87.89%.
| Gross Margin | 54.51% |
| Operating Margin | -77.45% |
| Pretax Margin | -87.89% |
| Profit Margin | -87.89% |
| EBITDA Margin | -76.02% |
| EBIT Margin | -77.45% |
| FCF Margin | n/a |
Dividends & Yields
Beta Bionics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -401.81% |
| Shareholder Yield | -401.81% |
| Earnings Yield | -6.42% |
| FCF Yield | -4.99% |
Analyst Forecast
The average price target for Beta Bionics is $28.09, which is 3.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.09 |
| Price Target Difference | 3.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 39.87% |
| EPS Growth Forecast (5Y) | -36.08% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Beta Bionics has an Altman Z-Score of 11.19 and a Piotroski F-Score of 2.
| Altman Z-Score | 11.19 |
| Piotroski F-Score | 2 |
